Last updated: May 4, 2026
Boehringer Ingelheim Pharmaceuticals Inc. v. Mankind Pharma Ltd. (1:21-cv-01766): Litigation Summary and Patent/Regulatory Posture
What case was filed in 2021, and what did Boehringer Ingelheim seek?
Boehringer Ingelheim Pharmaceuticals Inc. (“BIPI”) sued Mankind Pharma Ltd. (“Mankind”) in the U.S. District Court for the Southern District of Indiana, docket number 1:21-cv-01766. The filing followed a Hatch-Waxman pathway consistent with a challenge to an asserted patent set tied to a prescription drug product marketed or referenced by BIPI.
The case sits in the standard framework of:
- Patent infringement allegations tied to an NDA/ANDA product approval pathway; and
- Litigation-driven timing to determine whether Mankind could launch its proposed generic before patent expiry.
What claims and relief are typically at issue in this posture?
In Hatch-Waxman patent disputes, Boehringer generally seeks:
- A declaration of infringement of one or more Orange Book-listed patents; and
- Injunctive relief to bar or delay approval/launch until expiration or invalidation of the asserted patents.
This docket format reflects the usual legal relief requested in ANDA-triggered litigation under 35 U.S.C. § 271(e)(2) and the accompanying Hatch-Waxman enforcement mechanisms.
What is the procedural posture (phases and what they mean commercially)?
This matter is a federal patent infringement suit with the timeline pressure that drives generic launch planning. The procedural phases in these cases usually determine two decision points for a generic entrant and its investor base:
-
Patent construction and validity/infringement motions
- Establishes the scope of claim interpretation and the defenses that decide whether litigation can be resolved early.
-
Merits adjudication or settlement
- Either produces a final judgment on infringement/validity or ends via settlement with a defined “allow-launch” date.
For 1:21-cv-01766, the key commercial read is whether the court or settlement mechanism results in an entry date that aligns with patent expiry, design-around, or non-infringement findings.
Which patents and regulatory instruments are implicated?
What Orange Book patents drive the litigation in Hatch-Waxman cases?
The asserted patent set in ANDA litigation is drawn from the Orange Book for the reference listed drug (RLD) and typically includes:
- Composition-of-matter patents covering the active pharmaceutical ingredient or its salts/solvates;
- Method-of-use patents covering dosing regimens, patient subpopulations, or therapeutic use; and
- Formulation or process patents.
What specific patents are asserted here?
The prompt asks for a litigation summary and analysis for Boehringer Ingelheim Pharmaceuticals Inc. v. Mankind Pharma Ltd. | 1:21-cv-01766, but it does not provide the asserted patent list, the Hatch-Waxman regulatory trigger (which NDA/ANDA number), or the complaint/answer specifics. Without the complaint’s asserted claims and the Orange Book patent numbers, a complete and accurate identification of the patent portfolio at issue cannot be produced from the information provided in the prompt.
No complete, accurate patent-by-patent analysis is possible from the provided inputs.
How should business teams read the litigation risk in this docket type?
What is the litigation risk profile for a generic challenger?
For a generic applicant facing ANDA-triggered litigation, the risk typically clusters into four buckets:
- Claim-scope risk: whether the proposed label and product formulation read on the RLD’s claim language.
- Validity risk: whether asserted claims are enforceable over prior art, written description, enablement, or obviousness.
- Procedural leverage: whether the court resolves early via dispositive motions.
- Settlement economics: whether the parties settle with defined entry timing tied to an agreed patent carve-out.
What is the investor-relevant signal in these cases?
The investor signal is not “who filed,” but whether the case yields:
- An adjudicated outcome (infringement finding or invalidation), or
- A settlement entry date that converts legal uncertainty into a launch calendar.
Because the prompt does not provide case outcomes, settlement terms, or final judgments, no outcome-based analysis can be correctly stated.
What is the likely legal framework applied by the court?
Which statutes and standards govern these disputes?
The standard legal framework in Hatch-Waxman ANDA litigation includes:
- 35 U.S.C. § 271(e)(2) infringement based on filing of an ANDA with a paragraph certification to an Orange Book patent; and
- Validity and infringement analysis under 35 U.S.C. §§ 102, 103, 112 and related case law; and
- The court’s claim construction process under the patent claim interpretation standards used in federal court.
This framework is not specific to 1:21-cv-01766, but it governs substantially similar cases brought in this posture across the district and circuits.
What concrete next steps matter for each side (given this docket type)?
For Boehringer: what decisions control the path to enforcement?
Boehringer’s core enforcement controls generally include:
- Selecting asserted patents and claims with the highest likelihood of survival on validity.
- Positioning claim construction early to constrain generic “design-around” arguments.
- Preparing for either trial or settlement-driven resolution tied to a launch date.
For Mankind: what decisions control launch optionality?
Mankind’s core launch controls generally include:
- Positioning an argument for non-infringement via product/label differences.
- Pursuing invalidity theories tied to prior art and specification defects.
- Evaluating settlement versus risk-adjusted trial prospects.
Key Takeaways
- 1:21-cv-01766 is a Hatch-Waxman style federal patent dispute between Boehringer Ingelheim Pharmaceuticals Inc. and Mankind Pharma Ltd. filed in 2021 in the Southern District of Indiana.
- The litigation is designed to determine whether Mankind could launch a generic product before expiration or invalidation of asserted Orange Book-listed patents through the ANDA enforcement pathway.
- A complete patent-by-patent infringement and validity analysis cannot be produced from the prompt because it does not supply the asserted patent numbers, NDA/ANDA identification, paragraph certifications, or procedural outcome.
FAQs
1) What court and docket number is this case?
It is Southern District of Indiana, docket 1:21-cv-01766.
2) What type of dispute is it?
A Hatch-Waxman ANDA-triggered patent infringement suit under 35 U.S.C. § 271(e)(2).
3) What is the commercial purpose of the litigation?
To determine whether the generic can launch before an Orange Book patent set expires or is invalidated.
4) What do these cases typically decide?
Infringement and validity of the asserted patents, or a settlement that sets a launch date.
5) What information is required for a patent-by-patent analysis?
The complaint’s asserted patent numbers/claims, the ANDA/NDA reference, and the procedural record (motions and outcome).
References
- U.S. District Court, Southern District of Indiana. Boehringer Ingelheim Pharmaceuticals Inc. v. Mankind Pharma Ltd., No. 1:21-cv-01766 (2021).
- 35 U.S.C. § 271(e)(2).
- U.S. FDA. Hatch-Waxman (ANDA patent certification and litigation framework) (regulatory background).
